ABSTRACT Ninety patients participated in a randomised, double blind, placebo controlled comparison of terfenadine with astemizole in the treatment of hay fever. They entered the trial as-a cohort before the grass pollen season 
Seasonal hay fever is a common complaint affecting at least 10% of the population in Britain' at some time in their lives. Many of the symptoms are due to the local release of the inflammatory vasoactive mediator histamine and H, antihistamines are widely prescribed for this condition. The beneficial effects of H, antihistamines are, however, often offset by their associated anticholinergic and central nervous system sedative effects. Recently two new H, antihistamines, terfenadine and astemizole, have been developed that are devoid of both anticholinergic and central sedative actions. This has been confirmed in several clinical trials2-5 and in detailed psychomotor and visuomotor coordination studies.6`These two H, antihistamines differ in that terfenadine is rapidly metabolised and excreted9 whereas astemizole has a prolonged half life," reflecting its irreversible binding to H, receptors and slow release from hepatic lysosomes."
The purpose of this study was to investigate the efficacy of terfenadine and astemizole when compared with placebo in controlling hay fever symptoms. Address 
Results
There was no significant difference in the numbers, age, or sex distribution of the patients allocated to the three treatment groups (table). On entry into the trial there was no significant difference between the two active treatment groups with respect to their skin reactivity to grass pollen and histamine (table) . The patients who received placebo had a slightly greater response to grass pollen (p < 0-01) but not histamine (table) . Grass pollen counts were low (<20/m3124 h) during the first week of the trial and rose to reach a sustained maximum in excess of 800/m3/24 h during June 18-22 then subsequently declined.
During the trial 23 patients sought alternative medication for symptom relief and withdrew from the trial (placebo 9, terfenadine and astemizole 7 each). Two patients also withdrew from the astemizole group because of unrelated illness (tonsillitis and glandular fever). There were no significant differences in the mean number of patient days of treatment between the three treatment groups: terfenadine 48-1 (SD 2.6). astemizole 45-6 (3.0), and placebo 44.9 (2.8) days.
VISUAL ANALOGUE SCORES
The mean daily visual analogue scores for running nose, sneezing, and itching eyes are illustrated in figure 1. Analysis of variance identified astemizole as being significantly better than placebo (p < 0-0001) and terfenadine (p < 0-0001) in alleviating each of the symptoms of running nose. sneezing and itching eyes. There was no difference between astemizole and placebo in the management of blocked nose, though both astemizole (p < 0.0001) and placebo (p < 0-0001) were significantly better than terfenadine in the management of this symptom (fig 2) . There were no differences in the use of clemastine between the three treatment groups.
SKINPRICK TESTS
In patients receiving astemizole the mean skin weal responses to histamine and grass pollen were reduced after eight weeks' treatment by 97% (p < 0.001) and 55% (p <0.001) respectively. The corresponding reductions seen in patients receiving terfenadine were 67% (p < 0.001) and 36% (p < 0-001) respectively. The reduction associated with astemizole was significantly greater than that seen with terfenadine for both the histamine weal (p < 0-01) and the grass pollen weal (p < 0.01 (fig 1) . The beneficial effects of astemizole compared with placebo for running nose, sneezing, and itching eyes but not blocked nose confirm the results of a previous trial using a less sensitive rating scale scoring system.5 By initiating treatment before the grass pollen season it has been possible to assess prevention of the development of hay fever symptoms. This is illustrated in figure 1 , which identifies a breakthrough of control between 18 and 22 June coinciding with the peak grass pollen count, which rose to above 800/m3/24 h (concentrations above 150/m3/ 24 h being associated with symptoms in most patients). The loss of symptomatic control could either be related to reversal of the H, receptor antagonism by release of large amounts of histamine into the affected tissues, associated with the high level of antigen We were unable to show any significant beneficial effect of terfenadine over that of placebo for the treatment of hay fever. Previous studies of terfenadine have compared it either with placebo or with other H, antihistamines, such as chlorpheniramine.23 '3'4 Most of these trials were of short duration, lasting only two to nine days, and not all identified significant improvement in symptoms over placebo. 2'4 An explanation for the lack of efficacy of terfenadine when compared with placebo or astemizole in this study cannot be related to bioavailability, as all preparations showed similar dissolution properties, and demonstrable circulating concentrations of terfenadine must have been achieved to produce inhibition of both histamine and grass pollen skin weal responses. The development of tolerance, although recognised with antihistamines,'5 is also unlikely as its profile of protection 672 compared with that of placebo did not alter throughout the pollen season (fig 1) . Little has been published on the pharmacokinetics of long term terfenadine treatment. With single dose studies 99.5% of the absorbed drug undergoes first pass metabolism, being biotransformed into two major metabolites, a carboxylic acid analogue of terfenadine that possesses some H1 antihistaminic activity and an aa-diphenyl-4-piperidinemethanol.9 In view of the extensive metabolism of terfenadine it is possible that its biotransformation may produce a metabolite that interferes with the activity of histamine N-methyltransferase or diamine oxidase, enzymes responsible for the metabolism of histamine. Inhibition of histamine N-methyltransferase activity is well recognised with some H1 antihistamines '6 and could account for the failure to gain symptomatic control with this drug despite its 67% inhibition of histamine induced skin weal.
This study confirms previous reports that both astemizole and terfenadine are without significant sedative side effects. It also confirms our previous finding that astemizole is significantly better than placebo for the control of hay fever symptoms, with the exception of blocked nose. In addition, this study identifies that astemizole taken once daily is significantly better than terfenadine for the control of hay fever symptoms. We consider that, in view of its potency and freedom from adverse effects, astemizole is the non-sedative H1 antihistamine of choice for the maintenance treatment of seasonal allergic rhinitis and conjunctivitis. 
